Study S003375

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA AND OVERWEIGHT OR OBESITY RECEIVING POSITIVE AIRWAY PRESSURE THERAPY (VESPER-OSA 1)

ClinicalTrials.gov record

Registration

Registration: NCT07823608
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 258
Start: 2026-09-17
Primary completion: 2028-04-30
Lead sponsor: Pfizer
Conditions: Apnea; Sleep Disorders; Overweight and/or Obesity
Interventions: DRUG:Berobenatide; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:VESPER-OSA 1

Registered primary outcomes

Change From Baseline in Apnea-Hypopnea Index (AHI) [baseline, Week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.